Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 11

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 11
---
Expenses were comprised of the following:

SCHEDULE OF ACCRUED EXPENSES

                              As of                              As of                              
                              March 31, 2025                     September 30, 2024                 
 ────────────────────────────────────────────────────────────────────────────────────────────────────
  Accrued payroll taxes       $                       4,241      $                           4,241  
  Accrued Interest                                  410,214                                362,533  
  Accrued Payroll                                 1,256,630                              1,256,630  
  Accrued Rent                                       40,000                                      -  
  Other Accrued Expenses                             41,423                                 41,423  
  Total                       $                   1,752,508      $                       1,664,827  

6. UNEARNED INCOME

Unearned
income is attributable to payments made to the Company and its wholly owned subsidiary pursuant to two license agreements for which income
is recognized over the terms of the agreement.

7. NOTES PAYABLE

Notes
Payable comprise of below:

(a)
RELATED PARTY

Notes
payable to related parties consisted of the following:

SCHEDULE
OF NOTES PAYABLE TO RELATED PARTIES

                                                       As of                      As  
                                              March 31, 2025                      of  
                                                                  September 30, 2024  
 ──────────────────────────────────────────────────────────────────────────────────────
  David Koos                                          63,948                   1,708  
  BST Partners                                        87,215                       -  
  Zander Therapeutics, Inc.                           59,200                  40,000  
  Total notes payable to related parties             210,363                  41,708  

$ 63,948 15

$ 15,000 10

$ 25,000 10

$ 10,000 10

$ 4,700 10

$ 4,500 10

Zander
Therapeutics, Inc, and the Company are under common control.

During
the quarter ended December 31, 2024 BST Partners lent the Company the $ 46,599 10

During
the quarter ended March 31, 2025 BST Partners lent the Company the $ 40,616 10

BST
Partners and the Company are under common control.

(b)
NON RELATED PARTY

Notes payable consisted of the following:

SCHEDULE
OF NOTES PAYABLE TO NON RELATED PARTY